Glycocalyx-Edited Stem Cell Infusion Cuts Fragility Fractures by 94% in First-in-Human Osteoporosis Trial
核心洞察
A first-in-human phase 1 trial in Cell reports that a single infusion of glycocalyx-edited autologous mesenchymal stromal cells was well tolerated in 10 women with advanced osteoporosis (搜索).
Fracture incidence fell from 8 events per year in the two years before infusion to 0.5 events per year in the two years after, a 94 percent reduction.
Bone biopsies at day 120 showed increased bone tissue area in 7 of 10 patients, alongside rises in bone formation biomarkers and improved trabecular bone density on imaging.
A single intravenous infusion of a patient's own bone-marrow cells, engineered in the laboratory to home to bone tissue, sharply reduced fragility fractures in women with advanced osteoporosis (搜索), according to a first-in-human phase 1 trial published in Cell.
The study, led by first author and hematologist José M. Moraleda of the University of Murcia (搜索) in Spain, treated 10 women aged 51 to 72 with advanced osteoporosis (搜索) and a history of fractures. Before treatment, participants experienced fractures of the spine, hips, arms and other bones every year or two on average; after the infusion, low-impact fractures occurred at a rate closer to once per decade.
"The results show that this treatment approach has an excellent safety profile and is feasible," the researchers write. "However, strikingly… the results also reveal a durable reduction in the incidence of fragility fractures accompanied by increased serum levels of bone neoformation biomarkers, coupled with radiographic and histomorphometric evidence of an osteorestorative effect within trabecular bone."
Engineering Osteotropism Through Glycocalyx Editing
Mesenchymal stem/stromal cells (搜索) (MSCs) are multipotent precursors to osteoblasts, the cells that create and repair bone, making them a theoretical candidate for bone-strengthening therapy. However, when cultured outside the body and returned intravenously, MSCs lack a surface molecule called sialylated Lewis X (搜索) (sLeX), which hampers their ability to find the bone marrow.
"In preclinical models, this deficit is correctable by MSC glycocalyx editing to enforce sialylated Lewis X (搜索) (sLeX) expression, thereby programming osteotropism," the researchers explain.
The approach builds on work by co-author Robert Sackstein, a regenerative-medicine specialist at the Miami Veterans Affairs Medical Center (搜索) in Florida, who in 2008 found that adding a sugar called fucose to these stem cell-like cells enabled them to seek out and enter bones, leading to skeletal tissue generation in mice. The added sugars usually disappear within about two days and are thought to work by fostering interactions between the MSCs and blood-vessel walls, slowing the cells so they can squeeze into the bone marrow.
According to the authors, few trials had tested MSCs for osteoporosis (搜索), and no trials in any disease had deliberately modified the cells to improve their trafficking ability. It took several years to fine-tune the manufacturing process and generate the required preclinical data before the trial could proceed. Clinical collaborators in Spain began the trial in 2015.
Trial Design and Outcomes
In the trial, bone marrow was extracted from each participant's hip. Their MSCs were isolated and cultured, then modified with a glycocalyx tweak designed to improve their ability to return to the bone marrow after reintroduction into the bloodstream. The edited cells were delivered back via intravenous infusion, and participants were monitored for approximately six years of follow-up in total.
The primary aim was safety. The experimental treatment was well tolerated, with no treatment-related adverse events reported.
Fracture outcomes were equally notable. "Though subjects in this study were clinically at 'very high risk' for recurrent fragility fractures, the refracture incidence dropped precipitously," the authors note. "Specifically, in comparing the time span of 2 years pre-infusion to 2 years post-infusion, the fracture incidence decreased from 8 events/year to 0.5 events/year – a 94 percent reduction in fragility fractures."
Bone tissue biopsies taken 120 days after the MSC infusion showed a significant increase in average bone tissue area (BTA) for seven of the 10 patients. Bone metabolism biomarkers also showed signs of a bone-strengthening effect, and body imaging revealed improvements in the density of spongy trabecular bone.
"Collectively, the results suggest that the administered Fuc-autoBM-MSCs (搜索) mediate an osteoregenerative effect predominantly within trabecular bone," the researchers write. "This is a critical issue given that trabecular bone is far more metabolically active than cortical bone, and, accordingly, osteoporosis (搜索) predominantly disintegrates trabecular bone early in the disease, with a later erosion of cortical bone."
Caveats and the Path Forward
Independent observers greeted the results with enthusiasm tempered by methodological caution. "It's quite remarkable," says Ajit Varki, a physician-scientist at the University of California, San Diego who was not involved in the study. The trial "showed an almost 100% efficacy sustained for several years — and no side effects."
Still, the findings come with substantial caveats. The study was small, had no control group, and most participants were taking conventional osteoporosis (搜索) drugs before and during the trial, making it difficult to isolate the effects of the cell therapy. The researchers also did not directly track the therapeutic cells in recipients' bodies, leaving unanswered whether enough cells reached the bones to make a difference. Sackstein, however, is confident that they did.
The authors acknowledge that theirs is only a small study with a lack of diversity among participants, and they call for larger studies with broader diversity and more study sites. Given that this was primarily a safety trial rather than a randomized, controlled experiment, they say future studies will need to investigate the mechanism further and more formally measure the effects.
The context is substantial: osteoporosis (搜索) is estimated to affect as many as 500 million people worldwide, triggering up to 37 million fragility fractures a year — a bone breaking somewhere every second. The condition affects around 200 million women worldwide, particularly after menopause.
As far as the researchers are concerned, the results could mark the beginning of a paradigm shift. "Precision glycocalyx editing effectuates MSC-based therapy to reverse osteoporosis (搜索), thus potentially shifting therapeutic strategies for this disease from pharmacologic approaches to regenerative medicine," the authors write.